Summary
Danish drugmaker Novo Nordisk, which is expecting approval for the pill version of its anti-obesity treatment Wegovy in Europe later this year, has confirmed an investment of 432m in its manufacturing plant at Athlone.
Source: Independent.ie
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
